Rathbones Group PLC Sells 499,459 Shares of Edwards Lifesciences Corporation $EW

Rathbones Group PLC cut its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 79.5% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 128,616 shares of the medical research company’s stock after selling 499,459 shares during the period. Rathbones Group PLC’s holdings in Edwards Lifesciences were worth $10,059,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Brighton Jones LLC acquired a new stake in Edwards Lifesciences during the 4th quarter worth $266,000. Allworth Financial LP lifted its stake in shares of Edwards Lifesciences by 6.3% in the 1st quarter. Allworth Financial LP now owns 3,513 shares of the medical research company’s stock valued at $264,000 after purchasing an additional 208 shares during the period. Alps Advisors Inc. bought a new position in shares of Edwards Lifesciences in the 1st quarter worth $369,000. Cerity Partners LLC grew its stake in shares of Edwards Lifesciences by 67.9% during the first quarter. Cerity Partners LLC now owns 212,923 shares of the medical research company’s stock worth $15,433,000 after purchasing an additional 86,089 shares during the period. Finally, Arizona State Retirement System grew its stake in shares of Edwards Lifesciences by 0.8% during the first quarter. Arizona State Retirement System now owns 173,090 shares of the medical research company’s stock worth $12,546,000 after purchasing an additional 1,363 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Stock Up 1.1%

Edwards Lifesciences stock opened at $83.37 on Monday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. The company’s 50-day moving average is $77.78 and its 200-day moving average is $77.41. The firm has a market capitalization of $48.38 billion, a PE ratio of 12.00, a P/E/G ratio of 3.97 and a beta of 1.03. Edwards Lifesciences Corporation has a fifty-two week low of $64.89 and a fifty-two week high of $87.09.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. The business had revenue of $1.55 billion during the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.Edwards Lifesciences’s quarterly revenue was up 14.7% on a year-over-year basis. During the same quarter last year, the company posted $0.67 earnings per share. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. Sell-side analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Insider Activity at Edwards Lifesciences

In related news, insider Larry L. Wood sold 8,950 shares of the business’s stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the transaction, the insider directly owned 206,900 shares of the company’s stock, valued at approximately $16,150,614. The trade was a 4.15% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.29% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Stifel Nicolaus increased their target price on Edwards Lifesciences from $85.00 to $95.00 and gave the company a “buy” rating in a research note on Friday, October 31st. Raymond James Financial upgraded Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 price target for the company in a report on Monday, November 3rd. William Blair raised shares of Edwards Lifesciences to a “strong-buy” rating in a research report on Friday, July 25th. Evercore ISI increased their price objective on shares of Edwards Lifesciences from $88.00 to $92.00 and gave the stock an “outperform” rating in a research note on Friday, October 31st. Finally, BTIG Research upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and set a $100.00 price objective for the company in a report on Tuesday, July 29th. Three analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $91.39.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.